Amyloidosis Treatment Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

September 2025 | 94 pages | ID: ABECE705F470EN
Prof Research

US$ 3,200.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Amyloidosis Treatment Market Summary

The Amyloidosis Treatment market targets a rare protein misfolding disorder affecting 4,000 new cases annually in the U.S. alone, offering therapies that stabilize amyloid fibrils and halt organ damage with 70% progression-free survival. This sector is characterized by targeted agents like tafamidis for ATTR amyloidosis and daratumumab for AL types, compliant with FDA orphan drug designations. Key features include monoclonal antibodies with 80% response rates and supportive care integrating diagnostics like scintigraphy. The market serves hospitals and home settings, with 60% of treatments in specialized centers. Innovations like CRISPR-based gene silencing and bispecific antibodies enhance precision. The global Amyloidosis Treatment market is estimated to reach a valuation of approximately USD 4.0–6.5 billion in 2025, with compound annual growth rates projected in the range of 4.0%–9.0% through 2030. Growth is driven by improved diagnostics, expanding indications, and orphan incentives, positioning amyloidosis treatments as a high-value niche in rare disease care.

Application Analysis and Market Segmentation

Hospitals & Clinics

Hospitals deliver chemotherapy and immunosuppressants, growing at 4.5%–8.5%, with integrated diagnostics improving outcomes by 25%. Trends include multidisciplinary teams for ATTR management.

Ambulatory Surgical Centers

ASCs focus on supportive procedures, growing at 4%–8%, with outpatient infusions reducing costs by 20%.

Home Care Settings

Home care for oral therapies grows at 5%–9%, with telehealth monitoring.

Others

Research centers grow at 3.5%–7.5%, with trial integrations.

By Treatment

Chemotherapy

Chemotherapy for AL amyloidosis grows at 4%–8%, with bortezomib achieving 60% remission.

Immunosuppressive Drugs

Immunosuppressants grow at 4.5%–8.5%, with combinations enhancing efficacy by 30%.

Transplantation

Stem cell transplants grow at 3.5%–7.5%, with 80% long-term survival.

Supportive Care

Supportive therapies grow at 5%–9%, with symptom management kits.

Surgery

Surgical interventions grow at 3%–7%, for cardiac amyloid removal.

Others

Gene therapies grow at 4.5%–8.5%, with siRNA silencing.

Regional Market Distribution and Geographic Trends

Asia-Pacific: 5%–9% growth, with China's ATTR diagnostics and Japan's transplant programs.

North America: 4%–8% growth, with U.S. orphan drug access and Canada's research.

Europe: 3.5%–7.5% growth, with Germany's biologics and UK's NHS trials.

Latin America: 4.5%–8.5% growth, with Brazil's AL focus and Mexico's supportive care.

Middle East & Africa: 4%–8% growth, with UAE's specialized centers and South Africa's diagnostics.

Key Market Players and Competitive Landscape

Pfizer: $50B revenue, tafamidis leader for ATTR.

Alnylam Pharmaceuticals: Patisiran innovator, $2B sales.

Intellia Therapeutics: CRISPR-based therapies in trials.

GSK: $40B, supportive care specialist.

Johnson & Johnson Services: Daratumumab producer.

AstraZeneca: $40B, cardiac amyloid focus.

BridgeBio Pharma: ATTR stabilizers, $1B pipeline.

Merck: $60B, chemotherapy integrations.

Ionis Pharmaceuticals: RNA-targeted drugs.

Fortress Biotech: Rare disease specialist.

Takeda Pharmaceutical: $20B, oncology crossovers.

Amgen: $25B, biosimilar development.

Industry Value Chain Analysis

The value chain spans drug discovery, manufacturing, and patient delivery.

Raw Materials and Upstream Supply

Monoclonal antibodies from biotech suppliers, with Pfizer securing 500 kg annually.

Production and Processing

GMP facilities produce 100,000 doses yearly, with Alnylam ensuring 98% purity.

Distribution and Logistics

Cold-chain logistics achieve 95% success.

Downstream Processing and Application Integration

Hospitals: Infusion therapies.

Home Care: Oral agents.

Downstream yields 30% margins via orphan pricing.

End-User Industries

Patients capture value through 70% survival gains.

Market Opportunities and Challenges

Opportunities

Asia-Pacific's diagnostics growth drives treatments. Europe's rare disease funds boost biologics, while Latin America's centers expand. Gene silencing and biosimilars unlock affordability, and ATTR niches grow.

Challenges

High costs—$200,000 per year—limit access. Diagnostic delays slow treatment by 6 months. Side effect risks like neuropathy impact 10% of patients, while limited awareness in emerging markets caps penetration.
CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 ABBREVIATION AND ACRONYMS

CHAPTER 3 PREFACE

3.1 Research Scope
3.2 Research Sources
  3.2.1 Data Sources
  3.2.2 Assumptions
3.3 Research Method
Chapter Four Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users

CHAPTER 5 MARKET TREND ANALYSIS

5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats

CHAPTER 6 INDUSTRY CHAIN ANALYSIS

6.1 Upstream/Suppliers Analysis
6.2 Amyloidosis Treatment Analysis
  6.2.1 Technology Analysis
  6.2.2 Cost Analysis
  6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users

CHAPTER 7 LATEST MARKET DYNAMICS

7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics

CHAPTER 8 HISTORICAL AND FORECAST AMYLOIDOSIS TREATMENT MARKET IN NORTH AMERICA (2020-2030)

8.1 Amyloidosis Treatment Market Size
8.2 Amyloidosis Treatment Market by End Use
8.3 Competition by Players/Suppliers
8.4 Amyloidosis Treatment Market Size by Type
8.5 Key Countries Analysis
  8.5.1 United States
  8.5.2 Canada
  8.5.3 Mexico

CHAPTER 9 HISTORICAL AND FORECAST AMYLOIDOSIS TREATMENT MARKET IN SOUTH AMERICA (2020-2030)

9.1 Amyloidosis Treatment Market Size
9.2 Amyloidosis Treatment Market by End Use
9.3 Competition by Players/Suppliers
9.4 Amyloidosis Treatment Market Size by Type
9.5 Key Countries Analysis
  9.5.1 Brazil
  9.5.2 Argentina
  9.5.3 Chile
  9.5.4 Peru

CHAPTER 10 HISTORICAL AND FORECAST AMYLOIDOSIS TREATMENT MARKET IN ASIA & PACIFIC (2020-2030)

10.1 Amyloidosis Treatment Market Size
10.2 Amyloidosis Treatment Market by End Use
10.3 Competition by Players/Suppliers
10.4 Amyloidosis Treatment Market Size by Type
10.5 Key Countries Analysis
  10.5.1 China
  10.5.2 India
  10.5.3 Japan
  10.5.4 South Korea
  10.5.5 Southest Asia
  10.5.6 Australia

CHAPTER 11 HISTORICAL AND FORECAST AMYLOIDOSIS TREATMENT MARKET IN EUROPE (2020-2030)

11.1 Amyloidosis Treatment Market Size
11.2 Amyloidosis Treatment Market by End Use
11.3 Competition by Players/Suppliers
11.4 Amyloidosis Treatment Market Size by Type
11.5 Key Countries Analysis
  11.5.1 Germany
  11.5.2 France
  11.5.3 United Kingdom
  11.5.4 Italy
  11.5.5 Spain
  11.5.6 Belgium
  11.5.7 Netherlands
  11.5.8 Austria
  11.5.9 Poland
  11.5.10 Russia

CHAPTER 12 HISTORICAL AND FORECAST AMYLOIDOSIS TREATMENT MARKET IN MEA (2020-2030)

12.1 Amyloidosis Treatment Market Size
12.2 Amyloidosis Treatment Market by End Use
12.3 Competition by Players/Suppliers
12.4 Amyloidosis Treatment Market Size by Type
12.5 Key Countries Analysis
  12.5.1 Egypt
  12.5.2 Israel
  12.5.3 South Africa
  12.5.4 Gulf Cooperation Council Countries
  12.5.5 Turkey

CHAPTER 13 SUMMARY FOR GLOBAL AMYLOIDOSIS TREATMENT MARKET (2020-2025)

13.1 Amyloidosis Treatment Market Size
13.2 Amyloidosis Treatment Market by End Use
13.3 Competition by Players/Suppliers
13.4 Amyloidosis Treatment Market Size by Type

CHAPTER 14 GLOBAL AMYLOIDOSIS TREATMENT MARKET FORECAST (2025-2030)

14.1 Amyloidosis Treatment Market Size Forecast
14.2 Amyloidosis Treatment Application Forecast
14.3 Competition by Players/Suppliers
14.4 Amyloidosis Treatment Type Forecast

CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS

15.1 Pfizer
  15.1.1 Company Profile
  15.1.2 Main Business and Amyloidosis Treatment Information
  15.1.3 SWOT Analysis of Pfizer
  15.1.4 Pfizer Amyloidosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
15.2 Alnylam Pharmaceuticals
  15.2.1 Company Profile
  15.2.2 Main Business and Amyloidosis Treatment Information
  15.2.3 SWOT Analysis of Alnylam Pharmaceuticals
  15.2.4 Alnylam Pharmaceuticals Amyloidosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
15.3 Intellia Therapeutics
  15.3.1 Company Profile
  15.3.2 Main Business and Amyloidosis Treatment Information
  15.3.3 SWOT Analysis of Intellia Therapeutics
  15.3.4 Intellia Therapeutics Amyloidosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
15.4 GSK
  15.4.1 Company Profile
  15.4.2 Main Business and Amyloidosis Treatment Information
  15.4.3 SWOT Analysis of GSK
  15.4.4 GSK Amyloidosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
15.5 Johnson & Johnson Services
  15.5.1 Company Profile
  15.5.2 Main Business and Amyloidosis Treatment Information
  15.5.3 SWOT Analysis of Johnson & Johnson Services
  15.5.4 Johnson & Johnson Services Amyloidosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
15.6 AstraZeneca
  15.6.1 Company Profile
  15.6.2 Main Business and Amyloidosis Treatment Information
  15.6.3 SWOT Analysis of AstraZeneca
  15.6.4 AstraZeneca Amyloidosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
15.7 BridgeBio Pharma
  15.7.1 Company Profile
  15.7.2 Main Business and Amyloidosis Treatment Information
  15.7.3 SWOT Analysis of BridgeBio Pharma
  15.7.4 BridgeBio Pharma Amyloidosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
15.8 Merck
  15.8.1 Company Profile
  15.8.2 Main Business and Amyloidosis Treatment Information
  15.8.3 SWOT Analysis of Merck
  15.8.4 Merck Amyloidosis Treatment Revenue, Gross Margin and Market Share (2020-2025)
Please ask for sample pages for full companies list
TABLES AND FIGURES
Table Abbreviation and Acronyms
Table Research Scope of Amyloidosis Treatment Report
Table Data Sources of Amyloidosis Treatment Report
Table Major Assumptions of Amyloidosis Treatment Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Amyloidosis Treatment Picture
Table Amyloidosis Treatment Classification
Table Amyloidosis Treatment Applications
Table Drivers of Amyloidosis Treatment Market
Table Restraints of Amyloidosis Treatment Market
Table Opportunities of Amyloidosis Treatment Market
Table Threats of Amyloidosis Treatment Market
Table COVID-19 Impact for Amyloidosis Treatment Market
Table Raw Materials Suppliers
Table Different Production Methods of Amyloidosis Treatment
Table Cost Structure Analysis of Amyloidosis Treatment
Table Key End Users
Table Latest News of Amyloidosis Treatment Market
Table Merger and Acquisition
Table Planned/Future Project of Amyloidosis Treatment Market
Table Policy of Amyloidosis Treatment Market
Table 2020-2030 North America Amyloidosis Treatment Market Size
Figure 2020-2030 North America Amyloidosis Treatment Market Size and CAGR
Table 2020-2030 North America Amyloidosis Treatment Market Size by Application
Table 2020-2025 North America Amyloidosis Treatment Key Players Revenue
Table 2020-2025 North America Amyloidosis Treatment Key Players Market Share
Table 2020-2030 North America Amyloidosis Treatment Market Size by Type
Table 2020-2030 United States Amyloidosis Treatment Market Size
Table 2020-2030 Canada Amyloidosis Treatment Market Size
Table 2020-2030 Mexico Amyloidosis Treatment Market Size
Table 2020-2030 South America Amyloidosis Treatment Market Size
Figure 2020-2030 South America Amyloidosis Treatment Market Size and CAGR
Table 2020-2030 South America Amyloidosis Treatment Market Size by Application
Table 2020-2025 South America Amyloidosis Treatment Key Players Revenue
Table 2020-2025 South America Amyloidosis Treatment Key Players Market Share
Table 2020-2030 South America Amyloidosis Treatment Market Size by Type
Table 2020-2030 Brazil Amyloidosis Treatment Market Size
Table 2020-2030 Argentina Amyloidosis Treatment Market Size
Table 2020-2030 Chile Amyloidosis Treatment Market Size
Table 2020-2030 Peru Amyloidosis Treatment Market Size
Table 2020-2030 Asia & Pacific Amyloidosis Treatment Market Size
Figure 2020-2030 Asia & Pacific Amyloidosis Treatment Market Size and CAGR
Table 2020-2030 Asia & Pacific Amyloidosis Treatment Market Size by Application
Table 2020-2025 Asia & Pacific Amyloidosis Treatment Key Players Revenue
Table 2020-2025 Asia & Pacific Amyloidosis Treatment Key Players Market Share
Table 2020-2030 Asia & Pacific Amyloidosis Treatment Market Size by Type
Table 2020-2030 China Amyloidosis Treatment Market Size
Table 2020-2030 India Amyloidosis Treatment Market Size
Table 2020-2030 Japan Amyloidosis Treatment Market Size
Table 2020-2030 South Korea Amyloidosis Treatment Market Size
Table 2020-2030 Southeast Asia Amyloidosis Treatment Market Size
Table 2020-2030 Australia Amyloidosis Treatment Market Size
Table 2020-2030 Europe Amyloidosis Treatment Market Size
Figure 2020-2030 Europe Amyloidosis Treatment Market Size and CAGR
Table 2020-2030 Europe Amyloidosis Treatment Market Size by Application
Table 2020-2025 Europe Amyloidosis Treatment Key Players Revenue
Table 2020-2025 Europe Amyloidosis Treatment Key Players Market Share
Table 2020-2030 Europe Amyloidosis Treatment Market Size by Type
Table 2020-2030 Germany Amyloidosis Treatment Market Size
Table 2020-2030 France Amyloidosis Treatment Market Size
Table 2020-2030 United Kingdom Amyloidosis Treatment Market Size
Table 2020-2030 Italy Amyloidosis Treatment Market Size
Table 2020-2030 Spain Amyloidosis Treatment Market Size
Table 2020-2030 Belgium Amyloidosis Treatment Market Size
Table 2020-2030 Netherlands Amyloidosis Treatment Market Size
Table 2020-2030 Austria Amyloidosis Treatment Market Size
Table 2020-2030 Poland Amyloidosis Treatment Market Size
Table 2020-2030 Russia Amyloidosis Treatment Market Size
Table 2020-2030 MEA Amyloidosis Treatment Market Size
Figure 2020-2030 MEA Amyloidosis Treatment Market Size and CAGR
Table 2020-2030 MEA Amyloidosis Treatment Market Size by Application
Table 2020-2025 MEA Amyloidosis Treatment Key Players Revenue
Table 2020-2025 MEA Amyloidosis Treatment Key Players Market Share
Table 2020-2030 MEA Amyloidosis Treatment Market Size by Type
Table 2020-2030 Egypt Amyloidosis Treatment Market Size
Table 2020-2030 Israel Amyloidosis Treatment Market Size
Table 2020-2030 South Africa Amyloidosis Treatment Market Size
Table 2020-2030 Gulf Cooperation Council Countries Amyloidosis Treatment Market Size
Table 2020-2030 Turkey Amyloidosis Treatment Market Size
Table 2020-2025 Global Amyloidosis Treatment Market Size by Region
Table 2020-2025 Global Amyloidosis Treatment Market Size Share by Region
Table 2020-2025 Global Amyloidosis Treatment Market Size by Application
Table 2020-2025 Global Amyloidosis Treatment Market Share by Application
Table 2020-2025 Global Amyloidosis Treatment Key Vendors Revenue
Figure 2020-2025 Global Amyloidosis Treatment Market Size and Growth Rate
Table 2020-2025 Global Amyloidosis Treatment Key Vendors Market Share
Table 2020-2025 Global Amyloidosis Treatment Market Size by Type
Table 2020-2025 Global Amyloidosis Treatment Market Share by Type
Table 2025-2030 Global Amyloidosis Treatment Market Size by Region
Table 2025-2030 Global Amyloidosis Treatment Market Size Share by Region
Table 2025-2030 Global Amyloidosis Treatment Market Size by Application
Table 2025-2030 Global Amyloidosis Treatment Market Share by Application
Table 2025-2030 Global Amyloidosis Treatment Key Vendors Revenue
Figure 2025-2030 Global Amyloidosis Treatment Market Size and Growth Rate
Table 2025-2030 Global Amyloidosis Treatment Key Vendors Market Share
Table 2025-2030 Global Amyloidosis Treatment Market Size by Type
Table 2025-2030 Amyloidosis Treatment Global Market Share by Type
Table Pfizer Information
Table SWOT Analysis of Pfizer
Table 2020-2025 Pfizer Amyloidosis Treatment Revenue Gross Profit Margin
Figure 2020-2025 Pfizer Amyloidosis Treatment Revenue and Growth Rate
Figure 2020-2025 Pfizer Amyloidosis Treatment Market Share
Table Alnylam Pharmaceuticals Information
Table SWOT Analysis of Alnylam Pharmaceuticals
Table 2020-2025 Alnylam Pharmaceuticals Amyloidosis Treatment Revenue Gross Profit Margin
Figure 2020-2025 Alnylam Pharmaceuticals Amyloidosis Treatment Revenue and Growth Rate
Figure 2020-2025 Alnylam Pharmaceuticals Amyloidosis Treatment Market Share
Table Intellia Therapeutics Information
Table SWOT Analysis of Intellia Therapeutics
Table 2020-2025 Intellia Therapeutics Amyloidosis Treatment Revenue Gross Profit Margin
Figure 2020-2025 Intellia Therapeutics Amyloidosis Treatment Revenue and Growth Rate
Figure 2020-2025 Intellia Therapeutics Amyloidosis Treatment Market Share
Table GSK Information
Table SWOT Analysis of GSK
Table 2020-2025 GSK Amyloidosis Treatment Revenue Gross Profit Margin
Figure 2020-2025 GSK Amyloidosis Treatment Revenue and Growth Rate
Figure 2020-2025 GSK Amyloidosis Treatment Market Share
Table Johnson & Johnson Services Information
Table SWOT Analysis of Johnson & Johnson Services
Table 2020-2025 Johnson & Johnson Services Amyloidosis Treatment Revenue Gross Profit Margin
Figure 2020-2025 Johnson & Johnson Services Amyloidosis Treatment Revenue and Growth Rate
Figure 2020-2025 Johnson & Johnson Services Amyloidosis Treatment Market Share
Table AstraZeneca Information
Table SWOT Analysis of AstraZeneca
Table 2020-2025 AstraZeneca Amyloidosis Treatment Revenue Gross Profit Margin
Figure 2020-2025 AstraZeneca Amyloidosis Treatment Revenue and Growth Rate
Figure 2020-2025 AstraZeneca Amyloidosis Treatment Market Share
Table BridgeBio Pharma Information
Table SWOT Analysis of BridgeBio Pharma
Table 2020-2025 BridgeBio Pharma Amyloidosis Treatment Revenue Gross Profit Margin
Figure 2020-2025 BridgeBio Pharma Amyloidosis Treatment Revenue and Growth Rate
Figure 2020-2025 BridgeBio Pharma Amyloidosis Treatment Market Share
Table Merck Information
Table SWOT Analysis of Merck
Table 2020-2025 Merck Amyloidosis Treatment Revenue Gross Profit Margin
Figure 2020-2025 Merck Amyloidosis Treatment Revenue and Growth Rate
Figure 2020-2025 Merck Amyloidosis Treatment Market Share
......


More Publications